In the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results [NCT01179048]) clinical trial, the human GLP1-based analogue liraglutide or placebo were administered once daily as a subcutaneous injections to T2DM patients at high cardiovascular risk with a median follow-up of 3.8 years. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.